Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal groups a, c, y and w135 polysaccharide conjugate vaccine
- Development stage
- Unknown
- Lead developer
- Yuxi Watson Biotechnology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A quadrivalent conjugate vaccine designed to prevent invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, Y, and W-135. Developed by Yuxi Watson Biotechnology (a subsidiary of Walvax Biotechnology), it consists of capsular polysaccharides from each of the four serogroups individually conjugated to a tetanus toxoid carrier protein. This conjugation converts the T-cell independent polysaccharide antigens into T-cell dependent antigens, inducing a more robust immune response and immunological memory, particularly in infants and young children. It was approved in China in 2022 for use in children from 3 months to 3 years of age.
- Brand names
- MennoYuxi
- Other names
- MCV4-TTMCV-4-TTMCV 4-TTQuadrivalent Meningococcal Conjugate Vaccine
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)TT (Tetanus toxoid)
Beyond the preview
Go deeper on meningococcal groups a, c, y and w135 polysaccharide conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal groups a, c, y and w135 polysaccharide conjugate vaccine.